Navigation Links
Reports in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

CARLSBAD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced its financial results for the quarter ended June 30, 2009. During 2009 Isis has continued to successfully execute its business strategy and as a result reported $669...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

SAN CARLOS, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the second quarter ended June 30, 2009. Net loss for the quarter ended June 30, 2009 was $32.1 million or $0.35 per share, compared to net loss of $...

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

LEXINGTON, Massachusetts, August 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company, today reported positive results from the first of three Phase III studies of velaglucerase alfa, its enzyme replacement therapy in development fo...

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

PRINCETON, N.J., July 31 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) reported today positive preliminary results from its phase I clinical trial of PSI-7851 for the treatment of hepatitis C (HCV). PSI-7851 is a second generation nucleotide polymerase inhib...

Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms

COLLEGEVILLE, Pa., July 27 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), announced the publication in Fertility and Sterility of data from a Phase 3 clinical study that showed that the investigational compound bazedoxifene/conjugated estrogens...

BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza

BIRMINGHAM, Ala., July 17 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced positive results from two Phase 3 studies of intravenous (i.v.) peramivir in patients with seasonal influenza. The studies were sponsored by BioCryst's partner Shionogi & Co.,...

Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer

MARSEILLE, France, July 10 /PRNewswire-FirstCall/ -- Ipsogen SA (Alternext: ALIPS) today reported that the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer indicated for the first time that the Genomic Grade could be considered as an adjunct to the histolo...

BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis

TURKU, Finland, July 3 /PRNewswire/ -- BioCis Pharma Ltd., a privately held drug development company with its headquarters in Turku, Finland, announced positive results from its Phase IIa clinical trial of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. This dou...

PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans

MONTEREY, Calif., June 2 /PRNewswire/ -- This month's Journal of Aerosol Medicine and Pulmonary Drug Delivery features positive Phase Ib clinical trial results for PARI Pharma's L-CsA, inhaled liposomal cyclosporine A. In May, PARI Pharma received Orphan Drug Designation from the Food and Drug Ad...

Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

KRX-0401 + Capecitabine More Than Doubled Time to Progression and Overall Response Rate as well as Extended Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic Colon Cancer NEW YORK, May 31 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: ...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

KRX-0401 Demonstrates Impressive Single Agent Efficacy in Patients who Progressed after Failing Treatment Either with a VEGF Receptor Inhibitor or after Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor NEW YORK, May 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, I...

Spherix Reports First Quarter 2009 Earnings

BETHESDA, Md., May 14 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX ), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today reported results for the...

Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS(R) Liberte(R) Stent

Authors identify important differences between drug-eluting stent brands NATICK, Mass., May 11 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed the publication of an article in the current edition of the Journal of American College of Cardiology (JACC) rev...

BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results

BIRMINGHAM, Ala., May 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced that, based on discussions with the U.S. Department of Health and Human Services/Biomedical Advanced Research and Development Authority (HHS-BARDA), it is preparing a portion of its i...

Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status

Conference Call Scheduled for Today - Thursday, May 7, 2009 at 5:30 p.m. Eastern Time MOUNTAIN VIEW, Calif., May 7 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) reported today financial results for the quarter ended March 31, 2009, and provided an update on its prod...

Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update

- Conference Call Today at 5:00 p.m. Eastern Time - SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today reported financial results for the first quarter ended March 31, 2009, and ...

Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis

PARIS, May 4 /PRNewswire/ -- Fovea Pharmaceuticals announced today positive results from its clinical proof-of-concept trial to assess the therapeutic effect of Prednisporin(TM) (FOV1101) in patients with persistent allergic conjunctivitis. Prednisporin(TM) had the same efficacy and a better ...

Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine

EMERYVILLE, Calif., May 1 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today announced it has received a quarterly royalty payment of approximately $1.5 million from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of Alzheimer's...

Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams

SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE) , a San Diego based medical device company, announced today that Iowa's Des Moines Register published an article reporting that its LUMA cervical imaging system is enhancing the effectiveness of cancer ...

Clinician Reports Fast Healing of Intractable Wounds Using MEDIHONEY(R)

Jason Hanft of Baptist Health South Florida Reports on 11 Patients at SAWC PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Derma Sciences (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced that yesterday at the annual Symposium on the Advances in W...

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results

Conference Call and Webcast at 11:00 a.m. Eastern Time THE WOODLANDS, Texas, April 28 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its...

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

- With half as many injections, in two pivotal Phase 3 trials, Albuferon (albinterferon alfa-2b) met the primary efficacy endpoint of sustained virologic response comparable to Pegasys (peginterferon alfa-2a) - - Patients receiving 900-mcg Albuferon had comparable rates of serious and...

An Independent Study Reports on the Utility of ImmuKnow(R), the Cylex(TM) Immune Cell Function Assay, for Monitoring Heart Transplant Recipients

The results of the largest study performed to date will be presented during the International Society for Heart and Lung Transplantation Annual Meeting in Paris, France on April 24, 2009 COLUMBIA, Md., April 24 /PRNewswire/ -- Since it was cleared as an in vitro assessment of cell-mediate...

InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)

- Results inform selection of doses, regimens to be explored in Phase 2b study - -- Phase 2b program anticipated to begin in summer 2009 -- COPENHAGEN , April 24 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that results from a 14-day Phase 1b clinical stu...

Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication

Study shows Clonicel(R) and stimulants combined provide greater improvement in symptoms than stimulants alone DURHAM, N.C., April 23 /PRNewswire/ -- Addrenex Pharmaceuticals, Inc. today announced positive results from a second phase 3 trial of Clonicel demonstrating that the combination of Cl...

Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial

- Updated Data from Initial Cohort Shows 11 of 17 Evaluable Patients Receiving Bavituximab in Combination with Carboplatin + Paclitaxel Achieved an Objective Tumor Response - - Patient Dosing Initiated in Expansion Stage of Trial with Target of Enrolling 49 Patients Overall - TUSTIN, Cal...

Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack

SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM ) today reported on an NIH-funded, pre-clinical study conducted by independent researchers at the University of Cincinnati entitled IGF-1--Overexpressing Mesenchymal Stem Cells Accelerate Bone Marrow Stem Cell ...

Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update

- Conference Call Today at 5:00 p.m. Eastern Time - SOUTH SAN FRANCISCO, Calif., March 16 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today reported financial results for the fourth quarter and year ended Decembe...

DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program

CUPERTINO, Calif., March 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX ) announced today positive results from a 74 patient Phase IIb clinical trial conducted by Endo Pharmaceuticals of TRANSDUR(TM)-Sufentanil, a proprietary seven day patch under development for the treatment of ...

ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform

PARIS, March 16 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) today reported the publication in Lancet Oncology of a study conducted by Institut Gustave Roussy, which describes the identification of a deregulated cell function in breast cancer through the analysis of altern...

Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study

ATLANTA, March 12 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim 12-month safety and efficacy results from the first human ...

Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient

ANN ARBOR, Mich., March 9 /PRNewswire/ -- Terumo Heart, Inc. today announced that NewYork-Presbyterian Hospital/ Columbia University Medical Center recently became the second U.S. center, and first in the Northeast, to implant the DuraHeart(TM) Left-Ventricular Assist System as part of the DuraHe...

Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant

-Company Provides Update on Cash Position- -Biologics License Application for Wrinkles/Nasolabial Folds Indication Expected To Be Filed Within Two Weeks- EXTON, Pa., March 5 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE ) announced today positive top-line efficacy results ...

Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting

New subset analysis of bortezomib-relapsed patient population demonstrates 55% overall response rate and extended time to progression NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced updated clinical results from an ongoing Phase 1/2...

ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease

PARIS, February 26 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) is pleased to announce that clinical testing of EHT 0202, its lead compound in Alzheimer's disease, is progressing well. Patient enrolment for the Phase IIa trial assessing EHT 0202 in patients with Alzheimer'...

Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate

Results support that Novavax's Recombinant Technology May Offer a Powerful, New Approach for Development of the Next Generation of Influenza Vaccines with Broad Protection Against Multiple Strains ROCKVILLE, Md., Feb. 19 /PRNewswire-FirstCall/ -- NOVAVAX (Nasdaq: NVAX ) announced today favo...

Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer

PHILADELPHIA, and REHOVOT Israel, February 12 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq: ROSG ) reported today the first ever in-vivo efficacy data for a systemic microRNA-based cancer therapeutic. The animal-model study demonstrated a marked suppression of a microRNA that was f...

Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist

FREISING-WEIHENSTEPHAN, Germany, February 3 /PRNewswire/ -- Pieris AG, a biopharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, reports today that it has made significant progress in the development of its Anticalin(R) candidate PRS-050, a pot...

MannKind Reports Successful Completion of Device Bioequivalence Trial

VALENCIA, Calif., Jan. 13 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD ) today announced successful completion of its trial to demonstrate equivalence of its commercial inhaler to the version of the device that was used in clinical trials to deliver AFRESA(TM), MannKind's ultra...

AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety

Results Show Successful Clinical Validation of Pharmacodynamic Effect REDWOOD CITY, Calif., Jan. 12 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on the treatment of intermittent and acute medical conditions with an initial emphasis on pain...
Other Tags
(Date:9/18/2014)... invisible is probably the ultimate form of camouflage: you ... And this strategy is not as uncommon as you ... Baltimore County, USA, explains that the larval life stages ... one part of the anatomy that most creatures cannot ... eyes have to shield each individual eye unit with ...
(Date:9/18/2014)... the protective tentacles of host anemones, but new research ... kilometres across the open ocean. Although the process of ... is the first time that the high level exchange ... Dr Steve Simpson, Senior Lecturer in Marine Biology and ... from the Australian Research Council Centre of Excellence for ...
(Date:9/17/2014)... UCLA atmospheric scientists were instrumental in the creation of ... tool to classify the fire threat potential of the ... a spark into an inferno. The index was introduced ... with UCLA and San Diego Gas and Electric. , ... to "extreme" that will be used to help fire ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2
(Date:9/20/2014)... Recently, Best Cheap Hosting USA (best-cheap-hosting-usa.com), a leading ... The new site provides the latest reviews on ... Here, people can find a lot of information ... has recommended some excellent web hosting suppliers for ... web hosting suppliers, InMotion ( http://www.best-cheap-hosting-usa.com/go/InMotion/ ), keeps ...
(Date:9/20/2014)... PA (PRWEB) September 20, 2014 "As a ... in their tanks," said an inventor from Tamaqua, Pa. "The ... mounted on the backs of their chairs. My invention enables ... developed the Kam Oxygen Sensor to make it easier to ... that the user knows when the tank is low. It ...
(Date:9/20/2014)... Earlier this week, Home Depot revealed that up ... credit card information pilfered by hackers, surpassing the 40 million ... articles like this one published by Bloomberg on ... , “Most people tend to focus on how many ... to score a game,” says Joe Caruso, founder and CEO/CTO ...
(Date:9/20/2014)... September 20, 2014 Final Cut Pro ... the release of the Information theme for FCPX filmmakers. , ... to describe the Information theme,” says Christina Austin, CEO of ... look so professional.” , Information features easy to use controls ... of the environment. Change the background color, color of each ...
(Date:9/20/2014)... September 20, 2014 “Motherhood is a wonderful ... Snohomish in their latest article , “We know that ... you can—and that’s what we want to do as well.” ... need and should expect from their Family Physicians who practice ... of new motherhood. , To learn more about Community ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2
Other Contents